Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2017 1
2018 2
2019 1
2021 1
2022 3
2023 5
2024 1
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, Syed S, Li Y, Vargas WS, Turner TJ, Wallstroem E, Reich DS; HERCULES Trial Group. Fox RJ, et al. N Engl J Med. 2025 May 15;392(19):1883-1892. doi: 10.1056/NEJMoa2415988. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202696 Clinical Trial.
Spasticity Measurement.
Balci BP. Balci BP. Noro Psikiyatr Ars. 2018;55(Suppl 1):S49-S53. doi: 10.29399/npa.23339. Noro Psikiyatr Ars. 2018. PMID: 30692856 Free PMC article. Review.
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G; Frexalimab Phase 2 Trial Group. Vermersch P, et al. N Engl J Med. 2024 Feb 15;390(7):589-600. doi: 10.1056/NEJMoa2309439. N Engl J Med. 2024. PMID: 38354138 Clinical Trial.
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H; Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group. Oh J, et al. N Engl J Med. 2025 May 15;392(19):1893-1904. doi: 10.1056/NEJMoa2415985. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202623 Clinical Trial.
Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD).
Şen S, Kürtüncü M, Demir S, Gündüz T, Demirel E, Tütüncü M, Uzunköprü C, Cetinkaya Tezer D, Kızılay F, Balcı BP, Arslan G, Demir CF, Acar Özen NP, Beckmann Y, Güngör Doğan İ, Uygunoğlu U, Özakbaş S, Köseoğlu M, Gümüş H, Bilge N, Aksoy D, Kılıç AK, Yetkin MF, Akçalı A, Canbaz Kabay S, Ethemoğlu Ö, Tepe N, Çilingir V, Bunul SD, Kotan D, Gökçe ŞF, Bülbül NG, Akkoyun Arıkan F, Saip S, Terzi M, Efendi H, Karabudak R, Siva A, Tuncer A. Şen S, et al. Among authors: balci bp. J Neuroimmunol. 2025 Oct 15;407:578686. doi: 10.1016/j.jneuroim.2025.578686. Epub 2025 Jul 9. J Neuroimmunol. 2025. PMID: 40694990
Sleep Disorders in Patients with Epilepsy.
Mutlu A, Şişman AB, Günaydın S, Balcı BP. Mutlu A, et al. Among authors: balci bp. Noro Psikiyatr Ars. 2025 Jun 19;62(2):172-178. doi: 10.29399/npa.28732. eCollection 2025. Noro Psikiyatr Ars. 2025. PMID: 40583955 Free PMC article.
COVID-19-associated Isolated Cortical Vein Thrombosis: Detection of SARS-CoV-2 in CSF.
Oktar AÇ, Göçgün N, Yaşgüçlükal MA, Bayar MD, Alaçam S, Karabulut N, Duman EB, Şişman B, Baştan B, Balcı BP, Çokar Ö. Oktar AÇ, et al. Among authors: balci bp. Neurohospitalist. 2022 Jul;12(3):520-523. doi: 10.1177/19418744221079145. Epub 2022 Mar 4. Neurohospitalist. 2022. PMID: 35747763 Free PMC article.
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
Boz C, Ozakbas S, Terzi M, Karabudak R, Sevim S, Turkoglu R, Soysal A, Balcı BP, Efendi H, Turan ÖF, Yüceyar N, Yetkin MF, Karahan SZ, Demirkıran M, Guler S, Agan K, Kıylıoğlu N, Baba C, Tuncer A, Köseoğlu M. Boz C, et al. Among authors: balci bp. Neurol Sci. 2023 Jun;44(6):2121-2129. doi: 10.1007/s10072-023-06608-z. Epub 2023 Jan 23. Neurol Sci. 2023. PMID: 36689010
18 results